Want to see SEPN full AI Analyst Report?
SEPN Stock Chart & Stats
$41.30
$0.14(0.42%)
At close: 4:00 PM EDT
$41.30
$0.14(0.42%)
Day’s Range― - ―
52-Week Range$17.55 - $51.10
Previous CloseN/A
Volume33.99K
Average Volume (3M)375.50K
Market Cap
$1.79B
Enterprise Value$1.16B
Total Cash (Recent Filing)$372.32M
Total Debt (Recent Filing)$22.55M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Nov 25, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding46,676,950
10 Day Avg. Volume492,888
30 Day Avg. Volume375,497
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue11.72
Enterprise Value/Gross Profit11.77
Enterprise Value/Ebitda-29.46
Forecast
1Y Price Target
$52.88Price Target Upside28.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$97.64M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingRevenue more than doubled from 2025 to the latest trailing period, indicating meaningful commercial or partnership momentum. If sustained, this expanding base can improve operating leverage, support broader investment in the GPCR pipeline, and strengthen Septerna’s ability to fund development.
Strong Recent Cash GenerationPositive operating and free cash flow represent a major improvement from meaningfully negative levels in 2024 and earlier. This strengthens internal funding capacity for research and development, reduces immediate reliance on external capital, and provides financial support as the business advances.
Conservative LeverageVery low leverage limits fixed financial obligations and reduces balance-sheet risk while Septerna continues investing in development. Its sizable equity base and asset position provide flexibility to fund ongoing R&D and commercialization without the constraints associated with heavily debt-funded growth.
Bears Say
Persistent Net LossesSepterna remains unprofitable even after materially reducing its losses, showing that revenue growth has not yet translated into positive earnings. Continued net losses can constrain internally generated capital and indicate that the company still depends on successful scaling to reach sustainable profitability.
Cash-Flow Durability RiskThe latest cash-generation improvement is encouraging, but the slight year-over-year decline in free cash flow leaves its repeatability unresolved. The company will need to demonstrate continued positive cash conversion over future periods for this strength to represent a durable operating advantage rather than a temporary inflow pattern.
Negative Operating ProfitabilityHealthy TTM gross profitability of about 72.5% has not offset operating expenses, leaving the business in an investment-heavy phase with negative operating margins. Until revenue growth outpaces development and corporate costs, additional scale may not reliably produce earnings or sustained operating leverage.
Septerna, Inc. News
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $17.55 and its highest was $51.10 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $1.79B.
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Nov 25, 2026 which is in 44 days.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.426 by $0.136.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 46,676,950 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.426. Following the earnings report the stock price went up 22.934%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Septerna, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.88 (28.03% Upside)
$52.88 (28.03% Upside)
Blogger Sentiment
Neutral
SEPN Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 286.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $63.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.81%
12-Months-Change
Fundamentals
Return on Equity
-6.31%
Trailing 12-Months
Asset Growth
36.49%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
SEPN Stock 12 Month Forecast
Average Price Target
$52.88
▲(28.03% Upside)
Technical Analysis
Pharvaris
―
GH Research
―
Biohaven Ltd.
―
Structure Therapeutics, Inc. Sponsored ADR
―
Rapport Therapeutics, Inc.
―
Ownership Overview
6.12% Insiders
8.46% Mutual Funds
28.12% Other Institutional Investors
50.41% Public Companies and
Individual Investors